Fatih

Researchers are evaluating the accuracy of the straight leg raise test in adults suspected of having lumbosacral radicular pain, which often results from lumbar disc herniation and causes pain radiating from the lower back or buttock to the leg. This observational study uses diagnostic transforaminal epidural steroid injection or selective nerve root block as reference standards to measure the tests sensitivity, specificity, and overall diagnostic performance. Participants will undergo clinical evaluation including the straight leg raise test followed by diagnostic injections targeting the L4, L5, or S1 nerve roots. Only selective injections performed without sedation and with a low volume of short-acting local anesthetic are included. The study will analyze the diagnostic value of the straight leg raise test compared to these injections, helping to determine when the test alone is sufficient or when further diagnostics are necessary. During the study, participants will be assessed before and one hour after the diagnostic injection using the straight leg raise test, pain intensity scales, and the Bragard test. Additional evaluations include questionnaires, lumbar MRI analysis for disc degeneration and nerve root compression, and monitoring of any changes in symptoms. The study aims to provide detailed diagnostic insights, with participation expected to cover assessments during the diagnostic procedure and related clinical evaluations.

This research aims to evaluate how a structured productivity training program affects nurses perceived job stress and their attitudes toward productivity. The study is designed as a randomized controlled experimental trial with assessments before the training, immediately after, and three months later. Researchers want to see if nurses who receive the training report lower stress and better productivity attitudes compared to those who do not. The study involves two groups an experimental group that receives a three-week productivity training totaling 20 hours, and a control group that receives no training during the same period. The training covers nursing productivity concepts, time and stress management, teamwork, leadership, digital tools, and coping with job stress. Various teaching methods like lectures, case studies, simulations, and group work are used to improve cognitive, emotional, and practical skills. Participants will complete assessments using the Nurses Attitudes Toward Productivity Scale and the Perceived Job Stress Scale at three time points before training, right after the training, and three months later. The control group also completes these assessments without receiving training during the study but will get access to the training materials afterward. The total study duration includes the training period plus follow-up assessments to monitor lasting effects.

This observational study investigates how self-compassion and self-efficacy relate to symptom severity, functional ability, and quality of life in adults diagnosed with Parkinsons disease. The research aims to better understand these psychological factors in people living with Parkinsons disease stages 1 to 3, within an age range of 40 to 85 years. Participants will complete a set of self-report questionnaires during one session to assess their levels of self-compassion, self-efficacy, symptom severity, functional status, and quality of life. No therapeutic treatments or interventions are provided. The study collects data at a single time point to analyze associations among these outcomes. During the study visit, participants will be assessed with various scales and tests including the Self-Compassion Scale, Self-Efficacy for Managing Chronic Disease scale, Unified Parkinsons Disease Rating Scale, Timed Up and Go test, Six-Minute Walk test, Mini-Balance Evaluation Systems Test, and Parkinsons Disease Questionnaire-39. These assessments help evaluate physical function, symptoms, and quality of life. The study is led by Acibadem University and participation involves completing questionnaires and physical tests in one session.

Researchers are evaluating the Turkish version of the Heat Sensitivity Scale in individuals with Parkinsons disease. This cross-sectional observational study aims to examine the scales validity and reliability, including its internal consistency, test-retest reliability, and construct validity. The goal is to provide a trustworthy tool for assessing temperature sensitivity in Turkish-speaking people diagnosed with Parkinsons disease aged 40 to 85. Participants will complete assessments that include the Heat Sensitivity Scale and the Parkinsons Disease Questionnaire-39 PDQ-39. These measurements will be taken at baseline to evaluate their psychometric properties. No interventions or treatments are administered as part of this observational study. During the study, participants will attend assessments at the Movement Disorders Outpatient Clinic, where cognitive and communication abilities will be evaluated to ensure they can complete the questionnaires. Researchers will measure the Heat Sensitivity Scale total score and PDQ-39 total and subscale scores at the time of questionnaire completion. The study spans from May 2026 to May 2027, with the primary outcome measured at baseline.

Researchers are evaluating the safety and effectiveness of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This randomized, double-blind, placebo-controlled Phase 23 study includes multiple parts to assess different doses and durations of elenestinib treatment, including an open-label extension for participants finishing earlier phases. The study also enrolls participants who have previously received an approved selective KIT inhibitor and includes pharmacokinetic groups. Participants receive oral elenestinib or placebo once daily alongside SDT, which is personalized based on individual symptom management needs. Part 1 focuses on short-term treatment lasting up to 12 weeks, while Part 2 extends treatment to approximately 48 weeks. Part 3 and other parts allow treatment for up to about 5 years. The study monitors participants through these phases to evaluate how elenestinib affects symptoms, disease markers, and safety over time. During the study, participants undergo regular assessments of symptoms using the ISM-Symptom Assessment Form ISM-SAF, laboratory tests including serum tryptase and KIT D816V allele levels, bone marrow evaluations, and quality of life measures. Researchers track adverse events and changes in disease-related factors at various points up to 5 years. This thorough monitoring helps measure treatment effects and safety over both short and long-term periods, with total participation lasting several years depending on the study part.

This clinical trial studies children aged 6 to 12 with maxillary transverse deficiency, a condition causing dental crowding and crossbite. It compares two methods of maxillary expansion a traditional Rapid Maxillary Expansion RME using an acrylic cap splint with daily screw activations, and a modern digital Invisalign Palatal Expander IPE made with 3D printing that fits the palate and activates in smaller steps. The trial also includes a control group that does not receive expansion treatment. Participants are randomly assigned to three groups IPE, RME, or untreated controls. The IPE is a removable nylon device activated at 0.25 mm per step, while RME uses a bonded acrylic splint with a screw activated at 0.5 mm per day. Both treatment groups undergo expansion followed by retention. The control group receives no treatment during the study period. Three-dimensional intraoral and extraoral scans are taken at the end of expansion, at 3 months, and at 6 months. Participants will have scans to measure maxillary arch width, first molar angulation, palatal surface area, palatal volume, and facial soft tissue changes over time. These assessments help compare the effects of the two expansion methods and the untreated group. The study aims to provide evidence to guide orthodontic care in children with this condition. The total study duration extends through the 6-month retention period after expansion.

Researchers are evaluating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares the effects of combining two targeted therapies, belzutifan and zanzalintinib, against belzutifan with a placebo. The goal is to see if the combination can help people live longer and prevent the cancer from getting worse after other treatments have failed. Participants will take 120 mg of belzutifan orally and either 60 mg of zanzalintinib or a matching placebo once daily for about 24 months. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the active combination or placebo. Two groups are compared belzutifan plus zanzalintinib and belzutifan plus placebo. During the study, participants will be monitored for progression-free survival and overall survival, with assessments up to around 30 to 50 months. Researchers will also evaluate tumor response, duration of response, quality of life, and side effects. Safety and tolerability will be tracked throughout treatment and follow-up periods. The study is sponsored by Merck Sharp & Dohme LLC and aims to provide important information on treating advanced RCC.

Researchers are evaluating if combining the medicines calderasib and subcutaneous pembrolizumab can more effectively treat people with non-small cell lung cancer NSCLC that has a KRAS G12C mutation. The study aims to find out whether patients receiving calderasib with pembrolizumab live longer without their cancer growing or spreading compared to those receiving pembrolizumab with chemotherapy. This is a Phase 3 clinical trial focusing on first-line treatment for advanced or metastatic nonsquamous NSCLC. Participants are assigned to one of two groups. One group receives subcutaneous pembrolizumab plus berahyaluronidase alfa every 6 weeks for up to 18 cycles about 2 years along with oral calderasib until treatment discontinuation criteria are met. The other group receives the same pembrolizumab and berahyaluronidase alfa regimen plus chemotherapy with pemetrexed and either carboplatin or cisplatin infusions during the early cycles. Treatment continues based on individual response and tolerability. During the study, participants will have regular visits for treatment and monitoring. Researchers will assess progression-free survival, overall survival, response rates, and quality of life using questionnaires and symptom scores over several years. Safety will be monitored through adverse event reporting. The trial lasts up to about 7 years with ongoing evaluation of health outcomes and side effects to understand the impact of these treatment combinations.

Researchers are evaluating calderasib alone or combined with cetuximab to treat people with advanced solid tumors that have the KRAS G12C mutation, excluding colorectal cancer. This study aims to measure how many participants experience tumor shrinkage or disappearance and compare the responses between the two treatments. It is a phase 2, open-label trial focused on treatment safety and tolerability. Participants will receive calderasib orally with no set limit on treatment cycles. Some participants will also receive cetuximab via intravenous infusion every two weeks. Treatment continues until criteria for stopping the study intervention are met. The trial uses a randomized, parallel design to compare the two experimental arms. Throughout the study, participants will be monitored for tumor response, adverse events, and treatment discontinuations related to side effects. Researchers will also assess progression-free survival, duration of response, and overall survival up to about 76 months. The trial lasts until April 2032, with ongoing safety and efficacy evaluations during this period.

Researchers are studying treatments for locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific KRAS G12C gene mutation. This trial aims to evaluate if adding the targeted therapies calderasib and cetuximab to the standard chemotherapy regimen mFOLFOX6 can provide better outcomes compared to mFOLFOX6 with or without bevacizumab. The study focuses on the safety and tolerability of these combinations and whether they can help people live longer without their cancer growing or spreading. Participants will be assigned to one of two groups. One group will receive calderasib orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group will receive mFOLFOX6 chemotherapy with or without bevacizumab every two weeks, based on the investigators decision. Treatments will continue until certain stopping criteria are met. During the study, participants will be monitored for side effects and treatment tolerance, with regular assessments of cancer progression. Researchers will measure outcomes such as dose-limiting toxicities, adverse events, progression-free survival, and overall survival. Quality of life will also be evaluated through questionnaires. The study may last up to several years, with monitoring continuing for safety and effectiveness throughout the treatment period and follow-up.